1. Mo W*, Liu Q*, Dai H, Lin CJ, Peng Y, Liang Y, Meric-Bernstam F, Mills GB, Li K, and Lin SY. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple- negative breast cancer. (Clin Cancer Res. 2016 Apr 1;22(7):1699-712)
2. Liu Q, Russell MR, Shahriari K, Jernigan D, Lioni Mi, Garcia, F and Fatatis, A. Interleukin-1 promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Research 73, 3297 (2013)
3. Russell MR, Liu Q, and Fatatis A. Targeting the alpha receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clinical Cancer Research 16, 5002-5010 (2010)
4. Russell MR, Liu Q, Lei H, Kazlauskas A, and Fatatis A. The alpha receptor for platelet derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Research 70, 4195-4203 (2010)
